Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $110.76 on 10/9/25 after a major increase of 12.4%. Moreover, this advance was accompanied by exceptionally high trading volume at 207% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 15.0% during the last week.
Current PriceTarget Research Rating
Cidara Therapeutics has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Cidara Therapeutics has a very low Appreciation Score of 8 but a very high Power Rating of 94, and the Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment